Pharmaceutica Analytica Acta

Improved skin transport and hypoglycemic efficacy of Glimepiride transdermal patches

5^th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems

March 16-18, 2015 Crowne Plaza, Dubai, UAE

Osama A A Ahmed1,2, Tarek A Ahmed1,3, Mohsen I Afouna3, Ashraf B Abdel-Naim1, Alaa Khedr1 and Zainy M Banjar1

Posters & Accepted Abstracts: Pharm Anal Acta

Abstract:

Purpose: Utilization of hydroxybutyl- β-cyclodextrin (HB-β-CD) and polyvinyl pyrrolidone (PVP) in the enhancement of glimepiride (GMD) transdermal delivery. Methods: Matrix type transdermal patches containing GMD, drug coprecipitate or its inclusion complex were prepared using different gelling agents. The prepared patches were characterized, and in vitro skin permeation study for the test formulations was conducted using automated diffusion system. Prepared patches were assessed for their hypoglycemic activity and by determination of GMD plasma concentration in rats. Results: GMD- HB-β-CD binary systems (1:2 molar ratio) enhanced GMD aqueous solubility by more than 10 times. Diffusion studies showed improved release of GMD-HB-β-CD inclusion complex compared with its GMD alone. Permeability parameters of the prepared GMD patches, alone or as inclusion complex or co-precipitate through rat skin showed 26.973 and 14.28 μg/cm2 as maximum cumulative amounts of GMD permeated from patches, in the form of GMD- HB-β-CD, containing chitosan and HPMC, respectively. GMD complex-chitosan films showed significant (p< 0.05) improvement in permeation data compared with GMDHPMC data after 6 hours of permeation. Both chitosan and HPMC patches of GMD-HB-β-CD revealed substantial reductions (P< 0.05) in blood glucose levels (192.67?21.18) and (201?15.11) mg/dl from the base line value in 240 minutes, respectively. Conclusion: Application of chitosan and HPMC transdermal patches of GMD-HB-β-CD can be used as a valuable alternative to peroral GMD with improved bioavailability and patient compliance.